Loading your page…
Marketing-authorisation holder · United States
1 medicine in 1 country, as authorisation holder.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine in the registers under its name, current ones first.
1 medicine
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| PRANDIN0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Repaglinide | United States | Not marketed | 1997 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 1 | 1 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.
